31 results about "AIM antigen" patented technology

Embodiments of the present disclosure disclose an antigen-antibody binding conformation optimization method and device based on iterative closest point. A specific embodiment of the method comprises: obtaining a coarse-grained antibody file and a coarse-grained antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. The embodiment can improve the accuracy of the antibody conformation.

The invention provides a double-antibody directionally-coupled FET (Field Effect Transistor) biosensor and a preparation method thereof, and belongs to the technical field of biosensors. The FET biosensor adopts a reference electrode to provide grid voltage, a buffer solution is a conductive electrolyte, the FET biosensor comprises a field effect transistor, a capture antibody and a detection antibody, the field effect transistor is composed of a source electrode, a drain electrode and a channel between the source electrode and the drain electrode, the bottom layer of the channel is an indium oxide thin film layer, the indium oxide thin film layer is modified with amino, and the detection antibody is a detection antibody. An amino-modified channel is obtained; carrying out passivation treatment on the source electrode and the drain electrode by adopting a mercaptan passivator; and cross-linking and fixing the capture antibody and the detection antibody on the channel modified with the amino group through a cross-linking fixing agent to obtain the FET biosensor. The two antibodies are combined according to different epitopes of antigens to form a sandwich structure, and double recognition of the antibodies on target antigens is utilized to enhance antigen capture efficiency and signal enrichment, so that a double-site recognition mode is formed, and low-concentration antigen detection is realized.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

The invention discloses a PD-L1 kit based on proximity ligation and hybrid strand displacement and a detection method, and solves the technical problem of lack of a no-clean, ultra-sensitive and accurate detection method and kit for PD-L1. The kit provided by the invention comprises a monoclonal antibody for capturing a target antigen, an oligonucleotide chain, a detection probe and a hairpin probe. The detection method provided by the invention comprises the following steps: step 1, preparing a monoclonal antibody-DNA conjugate; step 2, establishing an HCR reaction system and amplifying a detection signal through HCR reaction; and step 3, detecting the HCR reaction product in the step 2 through a hairpin probe. The detection method has the advantages of no cleaning, ultra-sensitivity, high accuracy and the like.

The invention provides a low-abundance antigen detection method based on flow-type fluorescent single molecule counting, and belongs to the technical field of biological detection.The method comprises the following steps that after fluorescent encoding microspheres coated with captured antibodies are mixed with a standard sample or a sample to be detected, detection antibodies and nano magnetic beads are added, and the fluorescent encoding microspheres are obtained; or directly adding the nano magnetic beads coated with the detection antibody, reacting to form a double-antibody sandwich compound, separating the compound, and counting by adopting a flow cytometer; and establishing a standard curve of the antigen concentration and the collection number of the fluorescent microspheres, and calculating the concentration of the target antigen in the to-be-detected sample according to the standard curve. The method effectively improves the problem of low sensitivity of a flow fluorescence technology, is low in detection cost and reliable in detection result, and has important significance on low-abundance antigen detection.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The embodiments of the present disclosure relate to the optimization of an antibody generative model. A method for model training comprises: on the basis of information of a target antigen, using a current antibody generative model to generate a plurality of first antibodies; respectively determining antibody energies of the plurality of first antibodies; on the basis of the antibody energies of the plurality of first antibodies, constructing a plurality of first samples for the antibody generative model, wherein the plurality of first samples comprise at least one positive sample and at least one negative sample, an energy label corresponding to the first antibody in the positive sample indicates that the antibody energy thereof satisfies an energy preference associated with the target antigen, and an energy label corresponding to the first antibody in the negative sample indicates that the antibody energy thereof does not satisfy the energy preference; and using the plurality of first samples to execute fine tuning on the antibody generative model on the basis of an optimization objective, wherein the optimization objective is based on the discrepancy between predicted energy labels of antibodies generated by the fine-tuned antibody generative model and the energy labels of the plurality of first samples.

Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

Disclosed herein is a universal species-independent method for characterizing antibodies present in a sample that may provide protective immunity against a given pathogen or antigen of interest.

The application discloses a universal DC and a preparation method and application thereof, and belongs to the technical field of immune cells. The universal DC is obtained by knocking out HLA-I class genes in original DCs, and does not express HLA-I class molecules. In application, according to HLA-I class molecule typing of target antigen-specific T cells to be obtained, HLA-I class molecules matched with the target antigen-specific T cells are re-expressed in the universal DCs through gene editing, virus or mRNA technology, so that the limitation of HLA-I class molecule cell-specific matching of allogeneic DCs in application is overcome, and the problem of insufficient coverage of single DC HLA-I class molecule typing is solved.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gE (52-260aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody can realize specific recognition on gE protein and is used for detecting a target antigen in a sample. The antibody can be used as a core reagent in an immunodetection system, is suitable for laboratory detection and on-site rapid screening of porcine pseudorabies, is beneficial to improving the monitoring efficiency of basic-level and large-scale breeding links, and provides a technical guarantee for early discovery and accurate prevention and control of epidemic situations. Meanwhile, the antibody can also be used as a research tool to be applied to research on gE protein related biological functions and effects of the gE protein in a virus pathopoiesis process, and important support is provided for clarification of virus variation characteristics and optimization of subsequent prevention and control and diagnosis strategies.

The invention discloses an LSPR (Local Surface Plasmon Resonance) micro-fluidic chip system for rapid typing detection of various virus antigens, and particularly relates to the cross technical field of biomedical engineering, a micro-nano sensing technology, molecular diagnosis and micro-fluidic chip application. According to the present invention, by introducing the PEGylation anti-fouling layer and the BSA sealing treatment, the non-specific adsorption interference is effectively reduced, and compared with the problems that the traditional antigen rapid detection (Ag-RDT) is easily influenced by the virus epitope mutation and the variation is difficult to distinguish, the system can utilize the LSPR peak position red shift difference caused by the combination of different variation antigens and the specific antibody to achieve the precise typing of the multi-variant virus, meanwhile, white light dark field hyperspectral detection is combined with baseline correction, noise filtering and other algorithms, spectral signals can be accurately extracted, and even if interference components such as impurity protein and cell debris exist in a sample, feature signals of a target antigen can still be stably recognized.

The application relates to an antigen binding protein, an antibody or an antibody active fragment obtained by immunizing a camelid with a Sumo tag protein. The application relies on the immune system of the camelid to screen, identify and prepare an antibody specifically recognizing and binding the Sumo tag protein. The obtained antibody has high specificity and can be used for target antigen detection, and has potential clinical diagnosis and treatment values. The antibody provided by the application has simple structure, is easy to be genetically engineered, is easy to be humanized, has high stability, has low mass production cost, and is beneficial to realize large-scale production.

The present invention relates to methods for inhibiting the activity of a cellular immunotherapeutic in a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen, the method comprising:providing a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen;administering to the subject, a molecule for binding to the cellular immunotherapeutic, the molecule comprising or consisting of an epitope of the target antigen;wherein the epitope on the molecule competes with an epitope on the target antigen, for binding to the cellular immunotherapeutic and the molecule thereby disrupts the interaction between the cellular immunotherapeutic and the target antigen;thereby inhibiting the activity of the cellular immunotherapeutic in the subject.

The invention discloses an immunodetection probe, a kit and a detection method based on proximity ligation and nucleic acid amplification in the technical field of biological detection. The immunodetection probe comprises an antibody modified probe A, an antibody modified probe B and a splint probe, the antibody modification probe A comprises a first antibody and a first DNA chain, the antibody modification probe B comprises a second antibody and a second DNA chain, and the splint probe sequentially comprises a front end chain, a primer complementary chain and a rear end chain from the 5'end to the 3 'end; the first antibody and the second antibody can be specifically combined with different epitopes of the same target antigen to form a sandwich compound. By designing a double-hairpin closed probe with a synergistic effect, non-specific hybridization and connection are greatly inhibited from a molecular stress level by utilizing self-closing of a hairpin structure of the probe in an uncombined state and a specific open-loop mechanism under adjacent triggering, so that a background signal is remarkably reduced; the near-quantitative and high-efficiency formation of the circular DNA template is realized, and the uniformity and stability of signal generation are guaranteed.

A method of quantitatively analyzing an antigen includes a step of mixing an assay sample comprising a target antigen, magnetic particles on which a first antibody subjected to an antigen-antibody reaction with the target antigen is immobilized, and beads on which a second antibody different from the first antibody is immobilized; a step of adding dropwise the mixed assay sample to a microchip for quantitatively analyzing an antigen; a step of introducing the microchip into a digital inline microscope-based detector comprising a magnetic force applicator and applying magnetism to the magnetic force applicator; and a step of detecting the beads using images acquired in the detector to count the number of the target antigens.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

The present invention provides a novel CAR design containing a modified CD3ζ chain, and cells containing genetically modified immune-responsive cells (e.g., T cells, NK cells, or CTL cells) containing the CAR. [Solution] This disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. The CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide.

The present invention provides a method of quantitatively analyzing an antigen, the method comprising: a step of mixing an assay sample comprising a target antigen, magnetic particles on which a first antibody subjected to an antigen-antibody reaction with the target antigen is immobilized, and beads on which a second antibody different from the first antibody is immobilized; a step of adding dropwise the mixed assay sample to a microchip for quantitatively analyzing an antigen; a step of introducing the microchip into a digital inline microscope-based detector comprising a magnetic force applicator and applying magnetism to the magnetic force applicator; and a step of detecting the beads using images acquired in the detector to count the number of the target antigens.

Disclosed herein are binding polypeptides that bind to asialoglycoprotein receptor 1 (ASGR1), and methods of use thereof for inducing immune tolerance against antigens of interest, for example, for treating, ameliorating, inhibiting, or preventing disease or disorders associated with unwanted immune response against the antigens of interest, such as autoimmune diseases.

The invention discloses a novel immunodetection method and application. The immunodetection method comprises the following steps: coating a captured antibody and a single-site recognition antigen on a solid-phase carrier; adding a to-be-detected sample and a biotin-labeled mixed detection antibody for incubation, so that the target antigen forms a double-antibody sandwich compound, and the single-site recognition antigen and the detection antibody form a competitive compound; after streptavidin marked by chemiluminescence is added for incubation, signal values of the two compounds are detected; whether interference exists or not is judged and detected by comparing the double signals, and the content of the target antigen is determined. The immunodetection method can effectively identify cross interference and hook effect, and improves the accuracy and reliability of multi-index detection.

The utility model discloses an antigen and antibody purification device with a stacked elution structure, which comprises a mounting rack, the mounting rack is of a rectangular plate structure, a heating plate is mounted on the inner layer of the mounting rack, through holes are uniformly formed in the mounting rack, the through holes in the mounting rack are mounted with positioning buckles, and the positioning buckles are mounted on the mounting rack. And the positioning buckle and the mounting frame form a frame body structure for limiting the elution and purification device. According to the antigen and antibody purification device with the stacked elution structure, a first-order elution column, a second-order elution column and a third-order elution column are stacked in the device in the vertical direction to form a group of elution pieces, and along with communication between a shunt ring and a four-way valve pipe, a gradient elution structure is constructed in the device; by arranging eluents with different concentrations or different properties in different elution column superposition units, a complex and accurate elution gradient can be constructed, the elution efficiency of target antigens and antibodies is further improved through accurate gradient elution, and the purity of purified products is improved.

The application provides a computer-implemented method and device for tumor treatment strategy prediction, and belongs to the technical field of biological medicine. The method comprises the following steps: obtaining the proportion of target antigen-positive immune cells in total immune cells in a target sample; based on the difference between the proportion and a predetermined threshold, dividing the antigen expression level of the target sample to obtain a grouping result; wherein the grouping result is any one of N preset level groupings, and N is an integer not less than 1; based on the grouping result, matching a corresponding treatment strategy, wherein the treatment strategy comprises: administering an effective dose of an antibody corresponding to the target antigen and / or an immune checkpoint inhibitor antibody. By constructing a multi-level hierarchical mechanism based on the expression proportion of immune-related antigens and establishing a mapping relationship between the hierarchical result and the treatment strategy, fine immunotyping of tumor patients and individualized treatment strategy prediction are realized, so that the accuracy, safety and medical resource utilization rate of immunotherapy are improved.

The invention discloses a target epitope targeting antibody design method, and belongs to the technical field of artificial intelligence technology and computational structure biology technology, and the method comprises the following steps: step 1, epitope information acquisition: acquiring epitope site information on a target antigen structure by using a python code; step 2, mask driving; step 3, generating a conformation; 4, matching verification: carrying out simulated docking on the designed antibody and the target antigen in a digital space; and step 5, energy efficiency evaluation: calculating the binding energy of the designed antibody and the target antigen by using the code. According to the present invention, the template antibody sequence is redesigned by using the target antigen information and the target epitope information, such that the antibody sequence capable of targeting the designated epitope and having the high affinity can be designed; a large number of targeted antibodies to be selected are designed in a short time so as to reduce the harm possibly caused by pathogens.

A method of quantitatively analyzing an antigen includes a step of mixing an assay sample comprising a target antigen, magnetic particles on which a first antibody subjected to an antigen-antibody reaction with the target antigen is immobilized, and beads on which a second antibody different from the first antibody is immobilized; a step of adding dropwise the mixed assay sample to a microchip for quantitatively analyzing an antigen; a step of introducing the microchip into a digital inline microscope-based detector comprising a magnetic force applicator and applying magnetism to the magnetic force applicator; and a step of detecting the beads using images acquired in the detector to count the number of the target antigens.

The embodiment of the invention relates to a processing method and device for batch generation and screening tasks of homologous and isomeric antibodies. The method comprises the following steps: constructing a first generation model based on an RAAD model framework; constructing a first prediction model for predicting free energy and affinity characterization constants of the antigen-antibody compound; constructing a first data set and a second data set to train the first generation model and the first prediction model; after the training is finished, constructing a first isomeric graph based on a target antigen sequence, an original antibody sequence group and a target antigen-original antibody compound conformation specified by a user; and based on the batch number NB, the first isomeric map, the first generation model and the first prediction model, performing batch generation and screening processing on homologous isomeric antibodies of the original antibody to obtain an isomeric antibody priority sequence, and feeding back the isomeric antibody priority sequence to the current user. According to the invention, the abundance of the antibody can be improved, and the generation, analysis and screening efficiency of batch antibodies can be improved.

The embodiment of the invention discloses an antigen-antibody binding conformation optimization method and device based on an iterative closest point. A specific embodiment of the method comprises the following steps: obtaining a coarse graining antibody file and a coarse graining antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. According to the embodiment, the accuracy of antibody conformation can be improved.

The present invention discloses an apparatus, method, and computer-readable storage medium for designing humanized antibodies based on CDR transplantation. The method of the present invention obtains a CDR region-transplanted antibody by replacing the antigen complementary determining region sequence of a humanized antibody sequence with the antigen complementary determining region sequence of a heterologous antibody to a target antigen; performs single amino acid back mutation on the different amino acid sites between the CDR region-transplanted antibody and the heterologous antibody, and compares the structural difference scores of the three-dimensional structure of the protein before and after the mutation; retains the single amino acid back mutation sites with a structural difference score of less than or equal to 1, and finally obtains a CDR-transplanted humanized antibody for the target antigen. The method of the present invention can increase the similarity between the heterologous antibody and the human antibody sequence, reduce the immunogenicity of the human antibody to the target antigen, and maintain affinity.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a hypersensitive antibody detection method and kit based on collaborative optimization of magnetic particle coating, ALP cascade signal amplification and EDTA gradient washing. According to the technical scheme, carboxylated magnetic particles are activated through EDC / NHS and then covalently coupled with a target antigen, a signal is amplified through a cascade reaction of a biotinylated second antibody and ALP coupled streptavidin, the ALP catalytic efficiency is enhanced through a 4-MUP substrate containing 1 mM MgCl2, and gradient washing is conducted through a washing solution containing EDTA to eliminate background interference. The limitation of single module optimization is broken through, the signal / background ratio is larger than or equal to 50, and the detection limit is smaller than or equal to 0.5 ng / mL. Compared with the prior art, the sensitivity is improved by 10-20 times, and the antigen binding stability of the magnetic particles is remarkably improved (the magnetic particles are stored for 12 months at the temperature of 2-8 DEG C, and the performance degradation is smaller than or equal to 10%). The kit is suitable for early infection of pathogens such as mycoplasma pneumoniae and hypersensitivity detection of tumor markers.